S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NYSE:OGN

Organon & Co. (OGN) ESG Rating & Sustainability Data

$17.88
-0.38 (-2.08%)
(As of 09/25/2023 ET)
Compare
Today's Range
$17.82
$18.27
50-Day Range
$18.26
$23.77
52-Week Range
$17.82
$32.43
Volume
3.46 million shs
Average Volume
2.14 million shs
Market Capitalization
$4.57 billion
P/E Ratio
6.06
Dividend Yield
6.26%
Price Target
$28.25

Key ESG Takeaways for Organon & Co.

The keytakeaways are AI-generated and highlight the main contributors behind the net impact scores of Organon & Co.. The insights are based on millions of scientific articles, along with the company-specific product and service portfolio.
  • Organon seems to create the most significant positive value in categories , , and . The largest positive contribution comes from its impact, which is mostly driven by its Contraceptive implants, Thiazide diuretics, Simvastatin, Losartan, Ezetimibe, and Rizatriptan products.
  • Organon uses resources or causes negative impacts mostly in categories , , and . The largest negative impact of Organon in category seems to be driven mostly by its Contraceptive implants, Thiazide diuretics, Rizatriptan, Simvastatin, Alendronate, and Losartan products.
  • To improve its net impact, a company can either grow its positive impacts, or reduce its negative impacts. For example, by doubling its Simvastatin business, Organon would improve its net impact ratio by 1 percentage points.

OGN Impact Ratio

Net impact ratio represents the net impact of a company. It is defined as the (positive impacts - negative impacts) / positive impacts. The maximum value for net impact ratio is 100%, representing a theoretical company with no negative impacts. The minimum value is -∞. Net scores depend on the value sets that determine the importance of different impact categories.
+41.9%
The default value set, where each category is given the same weight.

Value Sets Value sets can be used to assess how different stakeholder values or emphasis on certain values might affect the net impact ratio.

Millennials
Value set of millennials (b. 1980 - 1999), based on Upright's annual Impact at Work survey.
+42.4%
Most Wanted Workforce
Value set of the most wanted workforce, based on Upright's annual Impact at Work survey.
+19.5%
Society First
Value set that emphasizes society impacts over other impacts.
-135.8%
Knowledge First
Value set that emphasizes knowledge impacts over other impacts.
+34.2%
Health First
Value set that emphasizes health impacts over other impacts.
+73.8%

Organon & Co. ESG Score + Net Impact Profile

ImpactNegativeScorePositive
+0.63
+0.63
+1.33
+1.33
+0.04
+0.04
-0.03
-0.03
+0.00
-1.05
-1.04
+0.02
0.00
+0.00
+0.03
+0.03
-0.00
+0.00
+0.00
-1.07
-1.07
-1.21
+5.95
+7.15
-0.07
+0.37
+0.44
+0.00
+0.00
-0.00
+0.01
+0.01
-0.01
+0.34
+0.35
-1.14
-1.10
+0.03
-0.68
-0.66
+0.01
-0.04
-0.04
+0.00
-0.15
-0.15
+0.00
-0.40
-0.40
+0.01

Upright Model Version 1.1.0
ESG Data Last Updated: June 14, 2023


About Upright's Net Impact Model

Upright's Net Impact Data quantifies the holistic value creation and impact of companies. It details both the negative and positive impacts a company has on the environment, health of people, society and knowledge, and forms a net sum of these costs and gains based on the economic costs of each impact category. The data is produced by Upright's Net Impact model, which is a mathematical model of the economy that produces continuously updated estimates of the net impact of companies by means of an information integration algorithm. The data is primarily sourced from the CORE open access database, which contains over 200 million scientific papers. Other sources of data include open databases published by the World Bank, IMF, WHO, OECD, IPCC, CDC and USDA.













Organon & Co. ESG Rating - Frequently Asked Questions

How is Organon & Co. doing in terms of sustainability?

According to The Upright Project, which measures holistic value creation and impact of companies, Organon & Co. has a net impact ratio of 41.9%, indicating an overall positive sustainability impact. Organon seems to create the most significant positive value in the categories of Physical diseases, Taxes, and Jobs. Organon uses resources or causes negative impacts mostly in the categories of Physical diseases, GHG emissions, and Scarce human capital. Learn more on the sustainability of Organon & Co..


More ESG Stocks and Research Tools

This page (NYSE:OGN) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -